2026年欧洲肝病学会（EASL）年会在巴塞罗那顺利举办，作为本届EASL大会秘书长，英国伦敦国王学院Debbie L. Shawcross教授接受了本次专访。如今EASL肝病大会早已跳出地域局限，完成全球化发展升级，汇聚世界各地肝病领域从业者，成为全球极具影响力的学术盛会。伴随疾病谱改变，全球肝病防控面临全新挑战，国际协作、学科发展与诊疗推进也成为行业关注重点。Shawcross教授围绕大会特色、EASL的国际价值、未来发展规划展开，同时谈及中外学术交流情况，全方位解读全球肝病领域发展态势，为业内同仁把握学科前沿、开展国际合作提供了重要参考。

《国际肝病》

作为本届EASL大会秘书长，本次大会在议程设置、交流形式与内容布局上有哪些独具特色的亮点？您现阶段最关注本次大会呈现的哪些肝病领域前沿话题与研究成果？

Shawcross教授：本次大会设置了丰富的学术科研、专业教育与行业倡导相关内容。大会核心亮点是完成了真正意义上的全球化发展。近十年来，EASL不再局限于欧洲本土肝病研究，全面深耕全球肝脏病学领域。

本届大会汇聚五大洲112个国家共8520名参会者，集结全球肝病领域学者，共研行业相关议题。各国学者带来了全新的学术视角、前沿技术与最新研究成果，赋予了大会独特的学术价值。

本次大会的一大特色是青年华人肝脏学者联盟在此举办首届成立会议，首次围绕中国青年科研人员的相关议题开展交流。同时，大会吸纳了拉美、非洲、亚洲等多地业内同仁，多元的地域视角让本次学术交流更为全面专业。

此外，大会设置的全球肝病海报巡展板块，聚焦全球各地区肝病领域的研究热点与前沿进展，覆盖各地特色研究方向，充分彰显了大会的全球学术代表性，也是我个人十分关注的创新板块。

Hepatology Digest: As Secretary-General of this year’s EASL Congress, what are the standout features in terms of agenda design, communication formats and content arrangement? Which cutting-edge topics and research findings in hepatology have caught your attention most at the congress?

Prof. Shawcross: This year’s congress encompasses a rich and diverse range of academic research, professional education and industry advocacy activities. Its core highlight is the achievement of genuine globalisation. Over the past decade, EASL has moved beyond European-focused hepatology research and devoted itself to advancing liver science across the globe.

The congress attracted 8,520 participants from 112 countries across five continents. Hepatology experts around the world gathered to discuss highly topical issues, bringing forward fresh academic perspectives, cutting-edge technologies and latest research outcomes, which have endowed the congress with unique academic value.

A major highlight was the inaugural meeting of the International Chinese Young Scholars Alliance for the Study of the Liver held during the event, which for the first time hosted in-depth discussions centering on young Chinese researchers. The congress also welcomed numerous professionals from Latin America, Africa, Asia and other regions. Diverse regional perspectives have made the academic exchanges more comprehensive and professional.

In addition, the Global Hepatology Poster Tour at the congress focused on research hotspots and latest progress in liver diseases from all regions, covering locally distinctive research directions. It fully embodies the congress’s global academic representativeness and is also an innovative segment that I fully embrace.

《国际肝病》

EASL大会是全球肝脏病学领域最具影响力的学术活动之一，多年来它在凝聚全球医务工作者、促进学术交流、统一临床诊疗认知层面，发挥了怎样不可替代的国际影响力？

Shawcross教授：EASL大会如今已成长为真正的全球性肝脏病学学术盛会。我在2002年首次参加EASL大会时，会议的地域局限性较强，主要聚焦欧洲区域，研究内容也仅围绕病毒性肝炎，并未覆盖肝脏病学的其他研究方向。

经过二十年、尤其是近十年的发展，EASL的学术体系已实现肝病领域全覆盖，涵盖肝硬化、病毒性肝炎、肝癌、行业倡导、基础科学等多个板块，今年更是新增肝移植与外科手术全新领域，进一步拓宽了学术边界，能够为参会的业内人士提供各细分领域的专属学术内容。

与此同时，大会始终聚焦全球共性肝病议题。当前全球肝病发病率快速攀升，我们长期致力于推动全球重视肝病问题，呼吁国际社会共同应对这一公共卫生挑战。

日前在日内瓦举办的第79届世界卫生大会上，一项重要决议于5月21日投票通过，正式将脂肪性肝病认定为非传染性疾病，并将其纳入全球非传染性疾病预防、管控与诊疗体系。这意味着肝病正式被列为全球重点非传染性疾病，各成员国可依托配套政策、协作网络与防控框架，系统性开展肝病防治工作。本次EASL大会也将此项内容列为重点，凝聚全球行业力量共同推进肝病防控工作落地。

Hepatology Digest: As one of the most influential academic events in global hepatology, what irreplaceable international impacts has the EASL Congress delivered over the years in uniting medical professionals worldwide, facilitating academic exchanges and unifying consensus on clinical diagnosis and treatment?

Prof. Shawcross: The EASL Congress has evolved into a truly global academic summit for hepatology. I first attended the EASL Congress in 2002. Back then, the event was heavily regionally constrained, mainly serving Europe, and its research scope was limited to viral hepatitis alone, with very little focus on other branches of hepatology.

After two decades of development — especially remarkable progress over the past ten years — EASL’s academic system now covers the full spectrum of liver diseases, including cirrhosis, viral hepatitis, liver cancer, cholestasis, public health and advocacy and basic science. This year, brand-new sessions on liver transplantation and hepatobiliary surgery have been added, further expanding the academic boundaries and providing targeted academic content for professionals in all sub-specialties.

Meanwhile, the congress always focuses on shared global challenges related to liver diseases. Given the rapidly rising prevalence of liver diseases worldwide, we have long strived to raise global awareness of liver health threats and call on the international community to jointly address this major public health issue.

On May 21, a key resolution was passed by vote at the 79th World Health Assembly in Geneva, officially recognising steatotic (fatty) liver disease as a non-communicable disease enabling it to be integrated into the global system for the prevention, control and management of non-communicable diseases. This means liver diseases are formally recognized as a major global non-communicable disease. Member states can now carry out systematic liver disease prevention and treatment with the support of relevant policies, collaborative networks and prevention frameworks. This important agenda has been listed as a key focus at this EASL Congress to mobilize global efforts to advance the implementation of liver disease prevention and control work.

《国际肝病》

面对全球肝病疾病负担持续变化的现状，您希望后续EASL及其年会继续在全球肝脏健康事业中承担起哪些关键作用？又将如何进一步深化国际间的协作联动？

Shawcross教授：EASL如同全球肝病领域的学术交流平台，汇聚了世界各地的肝病学界从业者，且我们的研究视野已从欧洲区域视角全面转向全球视角。当前全球肝病疾病负担持续攀升，虽然全球在乙肝、丙肝等传染性肝病的防控诊治上取得了长足进步，但非传染性肝病已逐渐成为主流疾病负担。以往影响较小的代谢相关脂肪性肝病、酒精性肝病，如今已成为全球肝病领域的重点问题，这也要求我们以全新的方式应对全新的临床与科研需求。

世界卫生组织提出了2030年全球消除病毒性肝炎的目标，目前亚洲地区在病毒性肝炎消除工作中成效突出，但部分地区仍存在诸多短板。基于此，EASL计划在未来三年重点推进病毒性肝炎的消除工作。本届大会已正式启动为期三年的病毒性肝炎HOPE消除行动计划，聚焦乙肝、丙肝、丁肝三大病毒性肝炎病种，凝聚全球肝病学界力量协同发力，助力全球病毒性肝炎的根除工作，这也是本次大会极具价值的全新举措。

Hepatology Digest: Faced with the continuously changing global burden of liver diseases, what key roles do you hope EASL and its annual congress will continue to play in advancing global liver health in the future? How will you further deepen international collaboration and coordination?

Prof. Shawcross: EASL acts as a core academic exchange platform for the global hepatology community, connecting practitioners from all over the world. Our research vision has fully shifted from a European perspective to a global one. While remarkable progress has been made worldwide in the prevention, diagnosis and treatment of infectious liver diseases such as hepatitis B and hepatitis C amid the growing global liver disease burden, non-communicable liver diseases have gradually become the dominant health challenge. Conditions that once posed limited threats, including metabolic dysfunction-associated fatty liver disease and alcohol-related liver disease, have now become major concerns in global hepatology, requiring us to adopt new approaches to meet evolving clinical and research demands.

The World Health Organization has set the goal of eliminating hepatitis C across the globe by 2030. Asia has achieved outstanding results in viral hepatitis elimination, though many gaps still exist in some other regions. Against this backdrop, EASL plans to prioritize viral hepatitis elimination over the next three years. This year’s congress has officially launched the three-year Viral HOPE Hepatitis Elimination Initiative, targeting three major types of viral hepatitis: hepatitis B, hepatitis C and hepatitis D. We aim to unite hepatologists worldwide to push forward the global eradication of viral hepatitis, which is another highly valuable new initiative of this congress.

《国际肝病》

中国肝病患者基数庞大，临床诊疗与科研发展速度备受国际瞩目。本次EASL年会上，您如何看待中国专家学者的参会表现与学术成果？

Shawcross教授：本届大会有大量中国学者参会，这是非常可喜的现象。我们高度重视中国及亚洲其他地区参会学者带来的学术力量。此前我也提到，青年华人肝脏学者联盟在本届大会举办成立会议，为全球肝病领域分享了中国肝病诊疗与研究的实际问题、本土视角与实践经验。

值得肯定的是，中国在肝病前沿研究、创新技术、人工智能，尤其是肝脏成像技术等领域发展迅猛，在肝癌疾病筛查识别、治疗方案研发等方面成果突出，已跻身全球领先水平。EASL始终积极接纳中国优质学术成果，并持续深化与中国学界的合作。

EASL旗舰期刊Journal of Hepatology目前的稿件最大来源地即为中国，这一数据直观体现了中国肝病领域强劲的科研实力。我们十分认可并感谢中国学界为本次大会作出的诸多贡献，也正是这些成果让本届大会更具价值与特色。

Hepatology Digest: China has a huge population of liver disease patients, and its rapid development in clinical care and scientific research has drawn wide international attention. What is your assessment of the participation and academic achievements of Chinese experts and scholars at this year’s EASL Congress?

Prof. Shawcross: We are delighted to see many Chinese scholars taking part in this congress. We highly value the academic strength brought by researchers from China and other parts of Asia. As I mentioned earlier, the inaugural meeting of the International Chinese Young Scholars Alliance for the Study of the Liver held here has shared real-world challenges, local perspectives and practical experience in liver disease diagnosis, treatment and research in China with the global community.

It is commendable that China has achieved rapid development in cutting-edge liver disease research, innovative technologies and artificial intelligence — especially liver imaging technology. Chinese researchers have reached world-leading recognition in liver cancer screening, identification and the development of therapeutic regimens. EASL always actively accepts high-quality academic achievements from China and continues to deepen cooperation with the Chinese hepatology community.

Currently, China is the largest source of manuscript submissions to Journal of Hepatology, EASL’s flagship journal. This figure directly demonstrates the strong research strength of China’s hepatology sector. We fully recognize and appreciate the tremendous contributions made by Chinese scholars to this congress, which have greatly enriched its value and features.

（来源：《国际肝病》编辑部）

声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。